TWI351950B - Use of (halobenzyloxy) benzylamino-propanamides fo - Google Patents

Use of (halobenzyloxy) benzylamino-propanamides fo Download PDF

Info

Publication number
TWI351950B
TWI351950B TW094127695A TW94127695A TWI351950B TW I351950 B TWI351950 B TW I351950B TW 094127695 A TW094127695 A TW 094127695A TW 94127695 A TW94127695 A TW 94127695A TW I351950 B TWI351950 B TW I351950B
Authority
TW
Taiwan
Prior art keywords
benzylamino
patent application
halobenzyloxy
propanamides
acceptable salt
Prior art date
Application number
TW094127695A
Other languages
English (en)
Other versions
TW200612894A (en
Inventor
Elena Barbanti
Florian Thaler
Carla Caccia
Ruggero Fariello
Patricia Salvati
Original Assignee
Newron Pharmaceuticala S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newron Pharmaceuticala S P A filed Critical Newron Pharmaceuticala S P A
Publication of TW200612894A publication Critical patent/TW200612894A/zh
Application granted granted Critical
Publication of TWI351950B publication Critical patent/TWI351950B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Description

• » I6·如申請專利範圍第1項之用途，其包括確定症狀及 預防性治療兩種處理方式。 Π·如申請專利範圍第1項之用途，其中，該單一（R)_ 異構物或其醫藥學上可接受之鹽係與一或多種其他治療 劑結合使用。 18.如申請專利範圍第口項之用途，其中，該其他治療 劑係選自加巴潘丁（ gabapent i η)及相關化合物。 φ 19·如申請專利範圍第17項之用途，其中，該其他治療 劑係為免疫系統調節物。 20. 如申請專利範圍第19項之用途，其中，該其他治療 劑係為干擾素。 21. 如申睛專利範圍第1項之用途’其係用於製造選擇 • 丨生/σ療疼痛症候群或偏頭痛之醫藥組成物，其包含醫藥學 ^可接受之載劑或稀釋劑以及（R)_2_[4_(2_氟苄氧基）苄 胺基]丙醯胺單一異構物及其醫藥學上可接受之鹽作為其 φ 活性劑。 22. 如申请專利範圍第a項之用途，其中，該醫藥學上 了接父之鹽係具有甲績酸的鹽。 23. 如申請專利範圍第21或22項之用途，其中，該疼 痛症候群係為神經病變性或發炎類型。 24. 如申請專利範圍第丨項之用途，其係用於製造選擇 ί±/α療疼痛症候群或偏頭痛之醫藥組成物，其包含作為單 ^異構物之（R)-2-[4-(2-氟苄氧基）苄胺基]丙醯胺或其 醤藥學上可接受之鹽，其中’該化合物之治療活性實質上 94127695
38 S 1351950 ^有任何MAO抑制副作用或呈現顯著降低的MA〇抑制副作 25. 如申請專利範圍第24項之用途，其中，該醫藥學上 可接受之鹽係具有甲磺酸的鹽。 26. 如申請專利範圍第24或25項之用途，其中，該疼 痛症候群係為神經病變性或發炎類型。 、 27. 如申請專利範圍第丨項之用途，其係用於製造選擇 • f治療疼痛症候群或偏頭痛之醫藥組成物，其包含作為單 一異構物之⑻+ [4_(2_鮮氧基作胺基]—卜甲基丙酸 上可接受之鹽，其中，該化合物之治療活性 貫質上沒有任何ΜΑ0抑制副作用或呈現顯著降低的MA〇抑 制副作用。 28. 如申請專利範圍第27項之用途，其中，該 • 可接受之鹽係具有甲磺酸的鹽。 29. 如申請專利範圍第27或28項之用途，其中，該疼 • 痛症候群係為神經病變性或發炎類型。 30·如申π專利範圍第1、8、9、i7、J 9及項中任一 項之用it其係用於製造選擇性治療多重硬化症之醫藥組 f物’其包含作為單一異構物之⑻_2-[4-(2-氟¥氧基） ¥胺基]丙醯胺紐）_2_[4_(2_鮮氧基胺基]|甲 基丙酿胺，或其醫藥學上可接受之鹽，其中，該化合物之 ⑺療活性實質上沒有任何MA〇抑制副作用或呈現顯著降 低的ΜΑ0抑制副作用。 31.如申請專利範圍第3〇項之用途其中，該醫藥學上 94127695 39 可接党之鹽係具有f磺酸的鹽。 32·如旁請專利範圍第】項之用 申請專利範®第i項中指定之任—疾病病=之於藥製^治其療 中’ 5亥病患係需要或期望無MAO抑制作用或顯著降低的 MAO抑制作用。
94127695 40
TW094127695A 2004-09-10 2005-08-15 Use of (halobenzyloxy) benzylamino-propanamides fo TWI351950B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04021525 2004-09-10

Publications (2)

Publication Number Publication Date
TW200612894A TW200612894A (en) 2006-05-01
TWI351950B true TWI351950B (en) 2011-11-11

Family

ID=34926488

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094127695A TWI351950B (en) 2004-09-10 2005-08-15 Use of (halobenzyloxy) benzylamino-propanamides fo

Country Status (28)

Country Link
US (2) US20080096965A1 (zh)
EP (1) EP1809271B9 (zh)
JP (1) JP5319920B2 (zh)
KR (1) KR101277520B1 (zh)
CN (1) CN101018546B (zh)
AR (1) AR050638A1 (zh)
AT (1) ATE471147T1 (zh)
AU (1) AU2005282028B2 (zh)
BR (1) BRPI0515154A (zh)
CA (1) CA2577408C (zh)
CY (1) CY1110770T1 (zh)
DE (1) DE602005021907D1 (zh)
DK (1) DK1809271T5 (zh)
ES (1) ES2347581T3 (zh)
HK (1) HK1105359A1 (zh)
HR (1) HRP20100400T1 (zh)
IL (1) IL181445A (zh)
ME (1) ME01801B (zh)
MX (1) MX2007002713A (zh)
NO (1) NO338713B1 (zh)
NZ (1) NZ553970A (zh)
PL (1) PL1809271T3 (zh)
PT (1) PT1809271E (zh)
RS (1) RS51411B (zh)
RU (1) RU2391973C2 (zh)
SI (1) SI1809271T1 (zh)
TW (1) TWI351950B (zh)
WO (1) WO2006027052A2 (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ531586A (en) * 2001-09-03 2005-09-30 Newron Pharm Spa Pharmaceutical composition comprising gabapentin or an analogue thereof and an alpha-aminoamide and its analgesic use
EP1438956A1 (en) * 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
KR101233711B1 (ko) * 2003-08-25 2013-02-18 뉴론 파마슈티칼즈 에스. 피. 에이. 항염증제로서 유용한 알파-아미노아미드 유도체
PT1809271E (pt) * 2004-09-10 2010-08-30 Newron Pharm Spa Utilização de (halogenobenziloxi)benzilamino-propanamidas para o fabrico de medicamentos activos como moduladores selectivos dos canais de sódio e/ou de cálcio
RS54522B1 (en) * 2005-12-22 2016-06-30 Newron Pharmaceuticals S.P.A. 2-Phenylethylamino Derivatives as Modulators of Calcium and (or Sodium) Channels
DK2474521T3 (en) 2006-06-19 2016-10-31 Newron Pharm Spa High-purity 2- [4- (3- and 2-fluorobenzyloxy) benzylamino] propanamides for use as pharmaceuticals and pharmaceutical formulations thus
ES2655704T3 (es) 2007-06-15 2018-02-21 Newron Pharmaceuticals S.P.A. Derivados de 2-[2-(fenil)etilamino]alcanoamida sustituidos y su uso como moduladores de canales de calcio y/o sodio
SI2229351T1 (en) 2007-12-11 2018-02-28 Newron Pharmaceuticals S.P.A. PROCEDURE FOR PREPARATION OF 2- (4- (3-OR 2-FLUOROBENYLOXYL) BENZYLAMINO) PROPANAMIDES WITH A HIGH PURITY Purity
WO2009080470A1 (en) * 2007-12-19 2009-07-02 Newron Pharmaceuticals S.P.A. Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders
WO2009109334A1 (en) * 2008-03-07 2009-09-11 Newron Pharmaceuticals S.P.A. (s)-(+)-2-[4-fluorbenzyloxy)benzylamino]propanamide for use in the treatment of mixed or combined pain
US9549967B2 (en) 2009-05-29 2017-01-24 The University Of North Carolina At Chapel Hill Regulation of sodium channels by PLUNC proteins
NZ602648A (en) * 2010-04-27 2014-10-31 Newron Pharm Spa Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers
WO2013000651A1 (en) 2011-06-27 2013-01-03 Newron Pharmaceuticals S.P.A. Fluorinated arylalkylaminocarboxamide derivatives
RU2017115994A (ru) 2014-10-08 2018-11-12 Дзе Юниверсити Оф Норт Каролина Эт Чепел Хилл Улучшенные пептидные ингибиторы натриевых каналов
RU2768149C2 (ru) 2017-06-20 2022-03-23 Раквалиа Фарма Инк. ПРОИЗВОДНЫЕ АМИДА В КАЧЕСТВЕ БЛОКАТОРОВ Nav1.7 И Nav1.8

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3451062A (en) * 1966-03-16 1969-06-24 Theodore Bradley Disposable examination gown
US3658967A (en) * 1966-06-23 1972-04-25 Ici Ltd Carboxylic acid derivatives for lowering the concentration of triglycerides in the blood
GB1140748A (en) * 1966-06-23 1969-01-22 Ici Ltd New carboxylic acid derivatives
CH480308A (de) * 1966-08-11 1969-10-31 Ciba Geigy Verfahren zur Herstellung von Thiosemicarbazid-Verbindungen
US4049663A (en) * 1972-06-06 1977-09-20 Allen & Hanburys Limited Ethylene diamine derivatives
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4311853A (en) * 1979-02-06 1982-01-19 The Radiochemical Centre Limited Selenium derivatives of thyroxine and tri-iodothyronine
DE3010599A1 (de) * 1979-03-22 1980-10-09 Continental Pharma Derivate von glycinamid, deren herstellung und verwendung
US4267354A (en) * 1979-04-25 1981-05-12 E. R. Squibb & Sons, Inc. Substituted amides having antiinflammatory activity and intermediates
CS234018B2 (en) * 1979-06-01 1985-03-14 Wellcome Found Method of 3,5-diammino-6-1,2,4-triazine derivatives making
FR2480747A1 (fr) * 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
DE3483308D1 (de) * 1983-11-21 1990-10-31 Fujisawa Pharmaceutical Co Semicarbazid-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
US4631287A (en) * 1985-04-16 1986-12-23 Usv Pharmaceutical Corp. Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
US4725619A (en) * 1985-04-16 1988-02-16 Usv Pharmaceutical Corporation Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
US4839369A (en) * 1985-04-16 1989-06-13 Rorer Pharmaceutical Corporation Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
GB8714901D0 (en) * 1986-07-23 1987-07-29 Ici Plc Amide derivatives
GB2216515A (en) * 1988-03-04 1989-10-11 Nippon Shinyaku Co Ltd Acylphenol derivatives
US4894476A (en) * 1988-05-02 1990-01-16 Warner-Lambert Company Gabapentin monohydrate and a process for producing the same
FR2639225B1 (fr) * 1988-11-21 1993-05-21 Centre Nat Rech Scient Compositions pharmaceutiques pour la neuroprotection contenant des arylcyclohexylamines
IL94466A (en) * 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
US5051403A (en) * 1989-11-22 1991-09-24 Neurex Corporation Method of treating ischemia-related neuronal damage
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
SG50624A1 (en) * 1991-12-30 1998-07-20 Neurex Corp Methods of producing analgesia and enhancing opiate analgesia
GB9203483D0 (en) * 1992-02-19 1992-04-08 Wellcome Found Anti-inflammatory compounds
US5330515A (en) * 1992-06-17 1994-07-19 Cyberonics, Inc. Treatment of pain by vagal afferent stimulation
US5256669A (en) * 1992-08-07 1993-10-26 Aminotek Sciences, Inc. Methods and compositions for treating acute or chronic pain and drug addiction
US5498610A (en) * 1992-11-06 1996-03-12 Pfizer Inc. Neuroprotective indolone and related derivatives
GB9306886D0 (en) * 1993-04-01 1993-05-26 Erba Carlo Spa Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation
GB9306899D0 (en) * 1993-04-01 1993-05-26 Erba Carlo Spa Substituted (arylalkylaminobenzyl) aminopropionamide derivatives and process for their preparation
US5475007A (en) * 1993-05-28 1995-12-12 The Regents Of The University Of California 1,2,3,4-tetrahydroquinoline-2,3,4-trione-3 or 4-oximes and the use thereof
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US5482964A (en) * 1994-10-11 1996-01-09 Warner-Lambert Company Substituted phenoxyhydroxypropyl amines as central nervous system agents
US5541204A (en) * 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
GB9426102D0 (en) * 1994-12-23 1995-02-22 Merck Sharp & Dohme Pharmacuetical compositions
KR0147963B1 (ko) * 1995-01-10 1998-08-17 강박광 엔-아릴알킬페닐아세트아미드 유도체와 그의 제조방법
GB9500691D0 (en) * 1995-01-13 1995-03-08 Smithkline Beecham Plc Compounds
US5849737A (en) * 1995-04-14 1998-12-15 The Regents Of The University Of California Compositions and methods for treating pain
US5741818A (en) * 1995-06-07 1998-04-21 University Of Saskatchewan Semicarbazones having CNS activity and pharmaceutical preparations containing same
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
US5795864A (en) * 1995-06-27 1998-08-18 Neurex Corporation Stable omega conopetide formulations
GB9515412D0 (en) * 1995-07-27 1995-09-27 Pharmacia Spa 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
US5688830A (en) * 1996-01-25 1997-11-18 Syntex (U.S.A.) Inc. Treatment of neuropathic pain
US6372792B1 (en) * 1996-04-26 2002-04-16 Guy Chouinard Method for treating anxiety, anxiety disorders and insomnia
AU4078897A (en) * 1996-08-23 1998-03-06 Algos Pharmaceutical Corporation Anticonvulsant containing composition for treating neuropathic pain
US6290986B1 (en) * 1996-10-24 2001-09-18 Pharmaceutical Applications Associates, Llc Method and composition for transdermal administration of pharmacologic agents
US6207685B1 (en) * 1996-12-06 2001-03-27 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Therapeutic application of a thienycyclohexylamine derivative
US6117841A (en) * 1997-05-30 2000-09-12 Warner-Lambert Company Substituted peptidylamine calcium channel blockers
AU8668598A (en) * 1997-08-20 1999-03-08 University Of Oklahoma, The Gaba analogs to prevent and treat gastrointestinal damage
IT1295423B1 (it) * 1997-10-10 1999-05-12 Medivis S R L Uso della flunarizina nella terapia topica del glaucoma
CA2310664C (en) * 1997-11-21 2008-03-11 Euro-Celtique S.A. Substituted 2-aminoacetamides and the use thereof
GB9727523D0 (en) * 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
GB9727521D0 (en) * 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Substituted 2-benzylamino-2-phenyl-acetamide compounds
US5905069A (en) * 1998-01-26 1999-05-18 The General Hospital Corporation Methods of decreasing or preventing pain using spicamycin or derivatives thereof
WO1999055688A1 (en) * 1998-04-27 1999-11-04 Warner-Lambert Company Substituted diarylalkyl amides as calcium channel antagonists
SE9801494D0 (sv) * 1998-04-28 1998-04-28 Astra Pharma Prod Novel use
US6011035A (en) * 1998-06-30 2000-01-04 Neuromed Technologies Inc. Calcium channel blockers
PL345340A1 (en) * 1998-07-09 2001-12-17 Warner Lambert Co Compositions comprising gaba analogs and caffeine
AU4329499A (en) * 1998-07-30 2000-02-21 Warner-Lambert Company Reduced dipeptide analogues as calcium channel antagonists
US6281211B1 (en) * 1999-02-04 2001-08-28 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
EP1200086A4 (en) * 1999-08-04 2009-05-27 Icagen Inc THERAPEUTIC OR PROPHYLACTIC METHODS OF PAIN AND ANXIETY
US6472530B1 (en) * 1999-09-22 2002-10-29 Ortho-Mcneil Pharmaceutical, Inc. Benzo-fused dithiepino[6,5-b]pyridines, and related compositions and methods
US6113915A (en) * 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
DE60103261T2 (de) * 2000-03-23 2005-06-02 Ortho-Mcneil Pharmaceutical, Inc. Thiepino[3,2-b]dihydropyridine und relatierte zusammensetzungen und verfahren
US6521647B2 (en) * 2000-04-04 2003-02-18 Pfizer Inc. Treatment of renal disorders
NZ531586A (en) * 2001-09-03 2005-09-30 Newron Pharm Spa Pharmaceutical composition comprising gabapentin or an analogue thereof and an alpha-aminoamide and its analgesic use
SI1458386T1 (sl) * 2001-12-27 2007-08-31 Ortho Mcneil Pharm Inc Aroil pirol heteroeril in metanoli, uporabni za zdravljenje motnje centralnega živčnega sistema
EP1438956A1 (en) * 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
CA2514574A1 (en) * 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Use of sodium channel modulators for treating gastrointestinal tract disorders
CA2514581A1 (en) * 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using sodium channel modulators
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
KR101233711B1 (ko) * 2003-08-25 2013-02-18 뉴론 파마슈티칼즈 에스. 피. 에이. 항염증제로서 유용한 알파-아미노아미드 유도체
EP1535908A1 (en) * 2003-11-24 2005-06-01 Newron Pharmaceuticals S.p.A. N-acyl-N'-benzyl-alkylendiamino drivatives
EP1557166A1 (en) * 2004-01-21 2005-07-27 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
EP1588704A1 (en) * 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
PT1809271E (pt) * 2004-09-10 2010-08-30 Newron Pharm Spa Utilização de (halogenobenziloxi)benzilamino-propanamidas para o fabrico de medicamentos activos como moduladores selectivos dos canais de sódio e/ou de cálcio

Also Published As

Publication number Publication date
IL181445A0 (en) 2007-07-04
US20110184068A1 (en) 2011-07-28
EP1809271B1 (en) 2010-06-16
TW200612894A (en) 2006-05-01
ES2347581T3 (es) 2010-11-02
RS51411B (en) 2011-02-28
MX2007002713A (es) 2007-05-23
PT1809271E (pt) 2010-08-30
ME01801B (me) 2011-02-28
DE602005021907D1 (de) 2010-07-29
JP5319920B2 (ja) 2013-10-16
EP1809271B9 (en) 2010-09-22
CN101018546B (zh) 2013-06-12
BRPI0515154A (pt) 2008-07-08
ATE471147T1 (de) 2010-07-15
WO2006027052A3 (en) 2006-05-26
KR20070061863A (ko) 2007-06-14
WO2006027052A2 (en) 2006-03-16
AR050638A1 (es) 2006-11-08
AU2005282028A1 (en) 2006-03-16
US20080096965A1 (en) 2008-04-24
AU2005282028B2 (en) 2011-03-24
IL181445A (en) 2014-03-31
CA2577408A1 (en) 2006-03-16
AU2005282028A2 (en) 2006-03-16
DK1809271T3 (da) 2010-09-20
SI1809271T1 (sl) 2010-10-29
RU2007113190A (ru) 2008-10-27
PL1809271T3 (pl) 2010-10-29
NZ553970A (en) 2010-01-29
DK1809271T5 (da) 2010-12-06
CY1110770T1 (el) 2015-06-10
RU2391973C2 (ru) 2010-06-20
HK1105359A1 (en) 2008-02-15
KR101277520B1 (ko) 2013-06-21
JP2008512405A (ja) 2008-04-24
CA2577408C (en) 2013-07-09
CN101018546A (zh) 2007-08-15
EP1809271A2 (en) 2007-07-25
NO338713B1 (no) 2016-10-03
HRP20100400T1 (hr) 2010-09-30
NO20071792L (no) 2007-06-11

Similar Documents

Publication Publication Date Title
TWI351950B (en) Use of (halobenzyloxy) benzylamino-propanamides fo
JP2021066744A5 (ja) ブプロピオンおよびデキストロメトルファンを含む組成物
JP2004531517A5 (zh)
JP2013542185A5 (zh)
JP2018521092A5 (zh)
JP2012520883A5 (zh)
JP2007514750A5 (zh)
ATE556061T1 (de) Therapeutisches oder prophylaktisches mittel gegen multiple sklerose
JP2009500045A5 (zh)
JP2021152008A5 (zh)
JP2002527474A5 (ja) 躁病および双極性障害の治療のための医薬
IL273169B1 (en) A new combination of active substances for the treatment of advanced lymphoid interstitial lung diseases
JP2019529541A5 (zh)
JP2014520893A5 (zh)
JP2024075655A5 (ja) 鏡像異性体的に純粋なブプロピオンの医薬の製造における使用
JP2022153638A5 (zh)
US20170216232A1 (en) Treating critically ill patients with intravenous ibuprofen
JP2011500776A5 (zh)
US6384083B1 (en) Use of adamantane amines or structurally similar compounds for combating borna disease virus and for the prevention and treatment of affective diseases and other disorders associated with bdv infections in humans and animals
WO2014078801A1 (en) Methods and compositions comprising guanidines for treating biofilms
JP2008526750A5 (zh)
RU2014112324A (ru) Применение органического соединения для лечения синдрома нунан
AU2010274030B2 (en) Treating patients with intravenous ibuprofen
JP2008513348A5 (zh)
CA2504665A1 (en) Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia